Cited by 657Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Open access

Eriksen, Jason L., Sagi, Sarah A., Smith, Tawnya E., Weggen, Sascha, Das, Pritam, McLendon, D.C., Ozols, Victor V., Jessing, Kevin W., Zavitz, Kenton H., Koo, Edward H., Golde, Todd E.·2003·Journal of Clinical Investigation

DOI 10.1172/jci18162PMC PMC166298

Open this paper in CoChat — free account Open PDF

Abstract

Epidemiologic studies demonstrate that long-term use of NSAIDs is associated with a reduced risk for the development of Alzheimer disease (AD). In this study, 20 commonly used NSAIDs, dapsone, and enantiomers of flurbiprofen were analyzed for their ability to lower the level of the 42-amino-acid form of amyloid beta protein (Abeta42) in a human H4 cell line. Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated. These studies show that (a). eight FDA-approved NSAIDs lower Abeta42 in vivo, (b). the ability of an NSAID to lower Abeta42 levels in cell culture is highly predicative of its in vivo activity, (c). in vivo Abeta42 lowering in mice occurs at drug levels achievable in humans, and (d). there is a significant correlation between Abeta42 lowering and levels of ibuprofen. Importantly, flurbiprofen and its enantiomers selectively lower Abeta42 levels in broken cell gamma-secretase assays, indicating that these compounds directly target the gamma-secretase complex that generates Abeta from APP. Of the compounds tested, meclofenamic acid, racemic flurbiprofen, and the purified R and S enantiomers of flurbiprofen lowered Abeta42 levels to the greatest extent. Because R-flurbiprofen reduces Abeta42 levels by targeting gamma-secretase and has reduced side effects related to inhibition of cyclooxygenase (COX), it is an excellent candidate for clinical testing as an Abeta42 lowering agent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci18162

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Glutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity
Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,959
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C.-M., Pérez‐Tur, J., Hutton, M., Buée, L., Harigaya, Y., Yager, D., et al. (1996) · Nature · doi:10.1038/383710a0 · Cited by 1,486

Flagged first, then by citations

Show all 52 references

Research works printed but not linked: 3

Wechter, 2000, Cancer Res., 60, 2203
Edbauer, 2003, Nat. Cell Biol., 7, 7
Murray, 2000, Clin. Pharmacol. Ther., 67, 103

Sorted by citations

Items 201–300 of 657

Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice
Rogers, K., Felsenstein, K. M., Hrdlicka, L., Tu, Z., Albayya, F., Lee, W., Hopp, S., Miller, M.-J., Spaulding, D., Yang, Z., et al. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-61 · Cited by 75
First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms
Borgegård, T., Juréus, A., Olsson, F., Rosqvist, S., Sabirsh, A., Rotticci, D., Paulsen, K., Klintenberg, R., Yan, H., Waldman, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.305227 · Cited by 75
Allosteric Modulation of PS1/γ-Secretase Conformation Correlates with Amyloid β42/40 Ratio
Uemura, K., Lill, C. M., Li, X., Peters, J. A., Ivanov, A., Fan, Z., Strooper, B. D., Bacskai, B. J., Hyman, B. T., & Berezovska, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007893 · Cited by 75
Current perspectives on pharmacotherapy of Alzheimer's disease
Chopra, K., Misra, S., & Kuhad, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.520702 · Cited by 75
An alternative interpretation of the amyloid Aβ hypothesis with regard to the pathogenesis of Alzheimer's disease
Marchesi, V. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503181102 · Cited by 74
Why Did Tarenflurbil Fail in Alzheimer's Disease?
Imbimbo, B. P. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1092 · Cited by 75
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74
Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase
Czirr, E., Cottrell, B. A., Leuchtenberger, S., Kukar, T. L., Ladd, T. B., Esselmann, H., Paul, S., Schubenel, R., Torpey, J. W., Pietrzik, C. U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802912200 · Cited by 72
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 72
Involvement of Prostaglandin E2 in Production of Amyloid-β Peptides Both in Vitro and in Vivo
Hoshino, T., Nakaya, T., Homan, T., Tanaka, K., Sugimoto, Y., Araki, W., Narita, M., Narumiya, S., Suzuki, T., & Mizushima, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703087200 · Cited by 74
Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer’s Disease – A Translational Perspective
Apetz, N., Münch, G. W., Govindaraghavan, S., & Gyengési, E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917110635 · Cited by 73
Targeting Microglia in Alzheimer’s Disease: Pathogenesis and Potential Therapeutic Strategies
Sun, Z., Zhang, X., So, K.-F., Jiang, W., & Chiu, K. (2024) · Biomolecules · doi:10.3390/biom14070833 · Cited by 71
DAPT-Induced Intracellular Accumulations of Longer Amyloid β-Proteins: Further Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase
Yagishita, S., Morishima‐Kawashima, M., Tanimura, Y., Ishiura, S., & Ihara, Y. (2006) · Biochemistry · doi:10.1021/bi0521846 · Cited by 71
β-Amyloid Precursor Protein Mutants Respond to γ-Secretase Modulators
Page, R. M., Gutsmiedl, A., Fukumori, A., Winkler, E., Haass, C., & Steiner, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103283 · Cited by 68
Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model
Meister, S., Zlatev, I., Stäb, J., Docter, D., Baches, S., Stauber, R. H., Deutsch, M., Schmidt, R., Ropele, S., Windisch, M., et al. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt225 · Cited by 73
The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer’s Disease
Qian, M., Shen, X., & Wang, H. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0232-4 · Cited by 71
Synthetic Transformation of 2-{2-Fluoro[1,1′-biphenyl]-4-yl} Propanoic Acid into Hydrazide–Hydrazone Derivatives: In Vitro Urease Inhibition and In Silico Study
Ahmad, S., Khan, M., Shah, M. I. A., Ali, M., Alam, A., Riaz, M., & Khan, K. M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05498 · Cited by 68
Progress of Alzheimer‚s disease
Lawrence, W. S. (2009) · Docs.school Publications · Cited by 68
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease
Gasparini, L., Ongini, E., Wilcock, D. M., & Morgan, D. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.029 · Cited by 68
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Therapeutic implications of the prostaglandin pathway in Alzheimer's disease
Cudaback, E., Jorstad, N. L., Yang, Y. J., Montine, T. J., & Keene, C. D. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.014 · Cited by 68
Heat Shock Protein 70: Roles in Multiple Sclerosis
Mansilla, M. J., Montalbán, X., & Espejo, C. (2012) · Molecular Medicine · doi:10.2119/molmed.2012.00119 · Cited by 70
Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures
Lanz, T. A., Fici, G. J., & Merchant, K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073965 · Cited by 66
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 67
Emerging perspectives on mitochondrial dysfunction and inflammation in Alzheimer’s disease
Yoo, S., Park, J., Kim, S., & Jung, Y. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.274 · Cited by 65
Obesity and Diabetes Mediated Chronic Inflammation: A Potential Biomarker in Alzheimer’s Disease
Khan, M. S. H., & Hegde, V. K. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020042 · Cited by 71
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology
van Groen, T., & Kadish, I. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.12.026 · Cited by 64
Untangling the Web: Toxic and Protective Effects of Neuroinflammation and PGE 2 Signaling in Alzheimer’s Disease
Woodling, N. S., & Andreasson, K. I. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00016 · Cited by 62
Asymmetric Hydrogenation of α-Substituted Acrylic Acids Catalyzed by a Ruthenocenyl Phosphino-oxazoline–Ruthenium Complex
Li, J., Shen, J., Xia, C., Wang, Y., Liu, D., & Zhang, W. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b00748 · Cited by 64
Acute Effect on the Aβ Isoform Pattern in CSF in Response to γ-Secretase Modulator and Inhibitor Treatment in Dogs
Portelius, E., Broeck, B. V., Andréasson, U., Gustavsson, M. K., Mercken, M. H., Zetterberg, H., Borghys, H., & Blennow, K. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100573 · Cited by 62
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 63
Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid‐β peptides via p75NTR/PLAIDD
Hashimoto, Y., Kaneko, Y., Tsukamoto, E., Frankowski, H., Kouyama, K., Kita, Y. A., Niikura, T., Aiso, S., Bredesen, D. E., Matsuoka, M., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02513.x · Cited by 63
Successes and Failures for Drugs in Late-Stage Development for Alzheimer’s Disease
Berk, C., & Sabbagh, M. N. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0108-6 · Cited by 63
Prostaglandin H2‐derived adducts of proteins correlate with Alzheimer's disease severity
Zagol-Ikapitte, I. A., Masterson, T. S., Amarnath, V., Montine, T. J., Andreasson, K. I., Boutaud, O. G., & Oates, J. A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03264.x · Cited by 62
Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease
Haas, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110986 · Cited by 61
New Therapeutic Targets in Alzheimer's Disease
Coman, H. G., & Nemeş, B. (2017) · International journal of gerontology · doi:10.1016/j.ijge.2016.07.003 · Cited by 63
The nuclear receptor PPARγ as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer's disease
Nicolakakis, N. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00021 · Cited by 60
APP Processing in Human Pluripotent Stem Cell-Derived Neurons Is Resistant to NSAID-Based γ-Secretase Modulation
Mertens, J., Stüber, K., Wunderlich, P., Ladewig, J., Kesavan, J., Vandenberghe, R. R., Vandenbulcke, M., Damme, P. V., Walter, J., Brüstle, O., et al. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.10.011 · Cited by 60
Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities
Girek, M. K., & Szymański, P. (2018) · Chemical Papers · doi:10.1007/s11696-018-0590-8 · Cited by 60
Protease inhibitors as potential disease-modifying therapeutics for Alzheimer’s disease
Beher, D., & Graham, S. L. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.11.1385 · Cited by 61
Consequences of Inhibiting Amyloid Precursor Protein Processing Enzymes on Synaptic Function and Plasticity
Wang, H., Megill, A., He, K., Kirkwood, A., & Lee, H. (2012) · Neural Plasticity · doi:10.1155/2012/272374 · Cited by 66
Nuclear receptor peroxisome proliferator‐activated receptor‐γ is activated in rat microglial cells by the anti‐inflammatory drug HCT1026, a derivative of flurbiprofen
Bernardo, A., Ajmone‐Cat, M. A., Gasparini, L., Ongini, E., & Minghetti, L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02932.x · Cited by 58
Mechanism of Action of Indomethacin in Indomethacin-Responsive Headaches
Summ, O., & Evers, S. (2013) · Current Pain and Headache Reports · doi:10.1007/s11916-013-0327-x · Cited by 58
Purification and properties of enantioselective lipase from a newly isolated Bacillus cereus C71
Shaoxin, C., Lili, Q., & Bing-zhao, S. (2007) · Process Biochemistry · doi:10.1016/j.procbio.2007.03.010 · Cited by 58
Lost in Translation: Neuropsychiatric Drug Development
Becker, R. E., & Greig, N. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000446 · Cited by 56
General Method for the 11C‐Labeling of 2‐Arylpropionic Acids and Their Esters: Construction of a PET Tracer Library for a Study of Biological Events Involved in COXs Expression
Takashima‐Hirano, M., Shukuri, M., Takashima, T., Goto, M., Wada, Y., Watanabe, Y., Onoe, H., Doi, H., & Suzuki, M. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200903044 · Cited by 58
γ-Secretase: a complex target for Alzheimer's disease
Lundkvist, J., & Näslund, J. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.10.002 · Cited by 58
Review: Experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology
Lee, D. C., Rizer, J., Hunt, J. B., Selenica, M. ‐. B., Gordon, M. N., & Morgan, D. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12002 · Cited by 57
Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease
Broeck, B. V., Chen, J., Tréton, G., Desmidt, M., Hopf, C., Ramsden, N. G., Karran, E. H., Mercken, M. H., & Rowley, A. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01207.x · Cited by 59
Novel modulators of amyloid‐β precursor protein processing
Tang, B. L., & Liou, Y. C. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04215.x · Cited by 57
The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer’s disease
Imbimbo, B. P. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.11.1469 · Cited by 54
Scope of direct arylation of fluorinated aromatics with aryl sulfonates
Chang, J. W. W., Chia, E. Y., Chai, C. L. L., & Seayad, J. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob06840k · Cited by 56
Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer’s disease-related symptoms and pathology
Hao, W., Liu, Y., Liu, S., Walter, S., Grimm, M. O. W., Kiliaan, A. J., Penke, B., Hartmann, T., Rübe, C. E., Menger, M. D., et al. (2010) · Brain · doi:10.1093/brain/awq325 · Cited by 54
γ-Secretase and the Intramembrane Proteolysis of Notch
Jorissen, E., & Strooper, B. D. (2010) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(10)92006-1 · Cited by 61
NSAIDs: how they work and their prospects as therapeutics in Alzheimer's disease
Sastre, M. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00020 · Cited by 57
Bepridil and Amiodarone Simultaneously Target the Alzheimer's Disease - and -Secretase via Distinct Mechanisms
Mitterreiter, S., Page, R. M., Kamp, F., Hopson, J., Winkler, E., Ha, H., Hamid, R., Herms, J. W., Mayer, T. U., Nelson, D. J., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1199-10.2010 · Cited by 55
Insensitivity to Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs and γ-Secretase Inhibitors Is Common among Aggressive Presenilin-1 Mutations
Czirr, E., Leuchtenberger, S., Dorner‐Ciossek, C., Schneider, A., Jucker, M., Koo, E. H., Pietrzik, C. U., Baumann, K., & Weggen, S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700618200 · Cited by 54
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease
Basi, G. S., Hemphill, S. S., Brigham, E. F., Liao, A., Aubele, D. L., Baker, J., Barbour, R., Bova, M. P., Chen, X., Dappen, M. S., et al. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt60 · Cited by 53
Coxibs and Alzheimer's disease: Should they stay or should they go?
Firuzi, O., & Praticò, D. (2006) · Annals of Neurology · doi:10.1002/ana.20774 · Cited by 54
γ-Secretase and its modulators: Twenty years and beyond
Xia, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.02.011 · Cited by 54
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.
Zhou, X., Li, Y., Shi, X., & Ma, C. (2016) · PubMed · Cited by 56
Cyclic Hydroxyamidines as Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines as Potent and Highly Efficacious γ-Secretase Modulators in Vivo
Sun, Z. J., Asberom, T., Bara, T. A., Bennett, C. E., Burnett, D. A., Chu, I., Clader, J. W., Cohen-Williams, M. E., Cole, D., Czarniecki, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201407j · Cited by 53
Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer’s Disease
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 55
Interplay between inflammation and degeneration: Using inclusion body myositis to study “neuroinflammation”
Dalakas, M. C. (2008) · Annals of Neurology · doi:10.1002/ana.21452 · Cited by 53
RETRACTED: Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice
Zhang, W., Bai, M., Ye, X., Hao, J., Zhang, Z., Su, C., Lei, G., Miao, J., & Li, Z. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.023 · Cited by 53
Retracted
Ene Reductase‐Catalysed Synthesis of (R)‐Profen Derivatives
Pietruszka, J., & Schölzel, M. (2012) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201100743 · Cited by 52
Enantioseparation of flurbiprofen on amylose-derived chiral stationary phase by supercritical fluid chromatography
Chen, W., & Rajendran, A. (2009) · Journal of Chromatography A · doi:10.1016/j.chroma.2009.02.047 · Cited by 52
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 53
Piperidine-derived γ-secretase modulators
Hall, A., Elliott, R. L., Giblin, G. M. P., Hussain, I., Musgrave, J., Naylor, A., Sasse, R. Z., & Smith, B. B. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.072 · Cited by 51
Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012
Pettersson, M., Stepan, A. F., Kauffman, G. W., & Johnson, D. S. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.821465 · Cited by 51
Alzheimer’s disease: Channeling APP to non-amyloidogenic processing
Tang, B. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.074 · Cited by 52
Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease
D’Onofrio, G., Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Paroni, G., Cascavilla, L., Seripa, D., & Pilotto, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.645534 · Cited by 52
Laccase/2,2,6,6‐Tetramethylpiperidinoxyl Radical (TEMPO): An Efficient Catalytic System for Selective Oxidations of Primary Hydroxy and Amino Groups in Aqueous and Biphasic Media
Díaz‐Rodríguez, A., Martínez‐Montero, L., Lavandera, I., Gotor, V., & Gotor‐Fernández, V. (2014) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201400260 · Cited by 50
Catalytic Asymmetric Synthesis Using Feedstocks: An Enantioselective Route to 2-Arylpropionic Acids and 1-Arylethyl Amines via Hydrovinylation of Vinyl Arenes
Smith, C. R., & RajanBabu, T. V. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo900198b · Cited by 50
γ-Secretase Modulators
Hall, A., & Patel, T. R. (2014) · Progress in medicinal chemistry · doi:10.1016/b978-0-444-63380-4.00003-2 · Cited by 49
Attenuated Aβ42 Responses to Low Potency γ-Secretase Modulators Can Be Overcome for Many Pathogenic Presenilin Mutants by Second-generation Compounds
Kretner, B., Fukumori, A., Gutsmiedl, A., Page, R. M., Luebbers, T., Galley, G., Baumann, K., Haass, C., & Steiner, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213587 · Cited by 49
Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein
Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C. A., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03327445 · Cited by 49
Dendrimeric Poly(Epsilon-Lysine) Delivery Systems for the Enhanced Permeability of Flurbiprofen across the Blood-Brain Barrier in Alzheimer’s Disease
Al-azzawi, S., Masheta, D., Guildford, A. L., Phillips, G., & Santin, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103224 · Cited by 49
Recent developments of small molecule γ-secretase modulators for Alzheimer's disease
Mekala, S., Nelson, G. L., & Li, Y. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00196a · Cited by 51
Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein
Yang, T., Arslanova, D., Gu, Y., Augelli‐Szafran, C. E., & Xia, W. (2008) · Molecular Brain · doi:10.1186/1756-6606-1-15 · Cited by 51
Blood–brain barrier penetration prediction enhanced by uncertainty estimation
Tong, X., Wang, D., Ding, X., Tan, X., Ren, Q., Chen, G., Rong, Y., Xu, T., Huang, J., Jiang, H., et al. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00619-2 · Cited by 49
Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection
Sharma, M., Pal, P., & Gupta, S. K. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105761 · Cited by 49
Integrated Pathways of COX-2 and mTOR: Roles in Cell Sensing and Alzheimer’s Disease
Tyagi, A., Kamal, M. A., & Poddar, N. K. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00693 · Cited by 50
Biomaterials-based anti-inflammatory treatment strategies for Alzheimer’s disease
Chu, J., Zhang, W., Liu, Y., Gong, B., Ji, W., Yin, T., Gao, C., Liangwen, D., Hao, M., Chen, C., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374137 · Cited by 48
The Potential Role of Rho GTPases in Alzheimer's Disease Pathogenesis
Bolognin, S., Lorenzetto, E., Diana, G., & Buffelli, M. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8637-5 · Cited by 47
Flurbiprofen ameliorated obesity by attenuating leptin resistance induced by endoplasmic reticulum stress
Hosoi, T., Yamaguchi, R., Noji, K., Matsuo, S., Baba, S., Toyoda, K., Suezawa, T., Kayano, T., Tanaka, S., & Ozawa, K. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303227 · Cited by 48
No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease
Hillmann, A., Hahn, S., Schilling, S., Hoffmann, T., Demuth, H., Bulic, B., Schneider-Axmann, T., Bayer, T. A., Weggen, S., & Wirths, O. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.08.006 · Cited by 46
β-Amyloid infusion results in delayed and age-dependent learning deficits without role of inflammation or β-amyloid deposits
Malm, T., Ort, M., Tähtivaara, L., Jukarainen, N., Goldsteins, G., Puoliväli, J. T., Nurmi, A., Pussinen, R., Ahtoniemi, T., Miettinen, T.-K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602896103 · Cited by 47
Alzheimer’s Disease and Genetics of Inflammation: A Pharmacogenomic Vision
Vasto, S., Candore, G., Duro, G., Lio, D., Grimaldi, M. P., & Caruso, C. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.12.1735 · Cited by 46
Plasma amyloid β protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy
Blasko, I., Kemmler, G., Krampla, W. W., Jungwirth, S., Wichart, I., Jellinger, K. A., Tragl, K. H., & Fischer, P. A. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.006 · Cited by 46
Ibuprofen modifies cognitive disease progression in an Alzheimer’s mouse model
Van Dam, D., Coen, K., & De Deyn, P. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097630 · Cited by 45
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update
Bales, K. R. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.666234 · Cited by 46
Novel γ-secretase modulators: a review of patents from 2008 to 2010
Pettersson, M., Kauffman, G. W., Ende, C. W. A., Patel, N. C., Stiff, C. M., Tran, T. P., & Johnson, D. S. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547479 · Cited by 45
Molecular Plasticity Regulates Oligomerization and Cytotoxicity of the Multipeptide-length Amyloid-β Peptide Pool
Vandersteen, A., Masman, M. F., Baets, G. D., Jonckheere, W., van der Werf, K., Marrink, ‪. J., Rozenski, J., Benilova, I., Strooper, B. D., Subramaniam, V., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394635 · Cited by 46
Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases
Suksuphew, S. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i2.502 · Cited by 46
Molecular Insights into Therapeutic Potentials of Hybrid Compounds Targeting Alzheimer’s Disease
Jana, A., Bhattacharjee, A., Das, S. S., Srivastava, A., Choudhury, A., Bhattacharjee, R., De, S., Perveen, A., Iqbal, D., Gupta, P. K., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02779-6 · Cited by 46
PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42
Boutaud, O. G., Montine, T. J., Chang, L., Klein, W. L., & Oates, J. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03586.x · Cited by 44
Piperlongumine Improves Lipopolysaccharide-Induced Amyloidogenesis by Suppressing NF-KappaB Pathway
Gu, S. M., Lee, H. P., Ham, Y. W., Son, D. J., Kim, H. Y., Oh, K. W., Han, S., Yun, J., & Hong, J. T. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8495-9 · Cited by 44

Authors: Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., & Golde, T. E.
Affiliations: Mayo Clinic (US)
University of California San Diego (US)
Corresponding author: Golde, Todd E.
ORCID: Eriksen, Jason L.
Weggen, Sascha
Das, Pritam
Koo, Edward H.
Golde, Todd E.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2003-08-01
Volume: 112
Issue: 3
Pages: 440-449
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci18162
PMC: PMC166298
OpenAlex: W2103071556
Cited by: 634
References: 52
Citations by year: 2026: 7 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 20 · 2020: 14 · 2019: 15 · 2018: 11 · 2017: 18 · 2016: 25 · 2015: 18 · 2014: 31 · 2013: 32 · 2012: 37
FWCI: 23.24
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Investigation (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Mayo Foundation for Medical Education and Research
National Institutes of Health
National Institute on Aging (P01AG020206, T32AG000216)
National Institute of Neurological Disorders and Stroke (R01NS039072)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: nonsteroidal anti-inflammatory drugs, gamma-secretase, amyloid-beta 42, Alzheimer's disease, APP transgenic mice, ibuprofen, meclofenamic acid, dapsone, cyclooxygenase inhibition, drug repurposing
MeSH terms: Alzheimer Disease, Animals, Anti-Inflammatory Agents, Non-Steroidal, Brain, Cell Line, Female, Flurbiprofen, Humans, Meclofenamic Acid, Mice, Transgenic, Peptide Fragments, Endopeptidases, Protease Inhibitors, Stereoisomerism, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks